1. Home
  2. CLLS vs MQT Comparison

CLLS vs MQT Comparison

Compare CLLS & MQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLLS
  • MQT
  • Stock Information
  • Founded
  • CLLS 1999
  • MQT 1992
  • Country
  • CLLS France
  • MQT United States
  • Employees
  • CLLS N/A
  • MQT N/A
  • Industry
  • CLLS Biotechnology: Pharmaceutical Preparations
  • MQT Investment Bankers/Brokers/Service
  • Sector
  • CLLS Health Care
  • MQT Finance
  • Exchange
  • CLLS Nasdaq
  • MQT Nasdaq
  • Market Cap
  • CLLS 240.2M
  • MQT 234.8M
  • IPO Year
  • CLLS 2007
  • MQT N/A
  • Fundamental
  • Price
  • CLLS $1.57
  • MQT $10.00
  • Analyst Decision
  • CLLS Buy
  • MQT
  • Analyst Count
  • CLLS 3
  • MQT 0
  • Target Price
  • CLLS $7.00
  • MQT N/A
  • AVG Volume (30 Days)
  • CLLS 56.7K
  • MQT 52.5K
  • Earning Date
  • CLLS 11-04-2024
  • MQT 01-01-0001
  • Dividend Yield
  • CLLS N/A
  • MQT 4.60%
  • EPS Growth
  • CLLS N/A
  • MQT N/A
  • EPS
  • CLLS N/A
  • MQT N/A
  • Revenue
  • CLLS $36,042,000.00
  • MQT N/A
  • Revenue This Year
  • CLLS $271.02
  • MQT N/A
  • Revenue Next Year
  • CLLS $33.48
  • MQT N/A
  • P/E Ratio
  • CLLS N/A
  • MQT N/A
  • Revenue Growth
  • CLLS 46.96
  • MQT N/A
  • 52 Week Low
  • CLLS $1.53
  • MQT $8.59
  • 52 Week High
  • CLLS $3.55
  • MQT $10.67
  • Technical
  • Relative Strength Index (RSI)
  • CLLS 27.91
  • MQT 25.97
  • Support Level
  • CLLS $1.85
  • MQT $10.45
  • Resistance Level
  • CLLS $2.09
  • MQT $10.67
  • Average True Range (ATR)
  • CLLS 0.09
  • MQT 0.12
  • MACD
  • CLLS -0.04
  • MQT -0.06
  • Stochastic Oscillator
  • CLLS 0.00
  • MQT 5.33

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

About MQT Blackrock MuniYield Quality Fund II Inc.

BLACKROCK MUNIYIELD QUALITY FUND II, INC. is a closed-end fund. Its objective is to provide shareholders with as high a level of current income exempt from federal income taxes as is consistent with its investment policies and prudent investment management. It invests in various sectors such as Transportation, Utilities, Health, County/City/Special District/School District, Education, Housing, Corporate, and Tobacco.

Share on Social Networks: